X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-08-27 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | CFO | S - Sale | $14.00 | -2,000 | 31,333 | -6% | -$27,992 | |||||
| M | 2025-08-27 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $13.99 | -5,029 | 413,304 | -1% | -$70,356 | |||||
| M | 2025-08-27 | AXSM | Axsome Therapeutics, Inc. | Jeffs Roger | Dir | S - Sale | $121.72 | -60,000 | 70,974 | -46% | -$7,303,400 | |||||
2025-08-22 | CYRX | Cryoport, Inc. | Hariri Robert J | Dir | S - Sale | $8.60 | -5,000 | 26,275 | -16% | -$43,000 | ||||||
2025-08-27 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Dir | S - Sale | $59.25 | -4,000 | 9,130 | -30% | -$237,000 | ||||||
| D | 2025-08-28 | XERS | Xeris Biopharma Holdings, Inc. | Sherman Jeffrey W | Dir | S - Sale+OE | $7.92 | -42,232 | 224,588 | -16% | -$334,515 | |||||
| D | 2025-08-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $20.63 | -3,250 | 23,000 | -12% | -$67,039 | |||||
| M | 2025-08-21 | AKTX | Akari Therapeutics Plc | Gaslightwala Abizer | CEO | P - Purchase | $0.93 | +21,000 | 298,574 | +8% | +$19,540 | |||||
| D | 2025-08-28 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Pres, CEO | S - Sale+OE | $49.39 | -25,000 | 305,871 | -8% | -$1,234,700 | |||||
| M | 2025-08-19 | PGEN | Precigen, Inc. | Agee Nancy H | Dir | P - Purchase | $3.79 | +26,005 | 202,841 | +15% | +$98,643 | |||||
| M | 2025-08-27 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale | $28.23 | -225,000 | 1,646,027 | -12% | -$6,352,743 | |||||
| D | 2025-08-27 | AGIO | Agios Pharmaceuticals, Inc. | Scadden David | Dir | S - Sale+OE | $40.00 | -200 | 17,603 | -1% | -$8,000 | |||||
| DM | 2025-08-27 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $45.10 | -34,800 | 2,098,233 | -2% | -$1,569,431 | |||||
2025-08-27 | SUPN | Supernus Pharmaceuticals, Inc. | Newhall Charles W III | Dir | S - Sale | $45.01 | -3,588 | 129,644 | -3% | -$161,496 | ||||||
2025-08-27 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bhatia Sangeeta N. | Dir | S - Sale | $386.69 | -266 | 4,565 | -6% | -$102,860 | ||||||
| M | 2025-08-26 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.79 | -4,109 | 4,418,768 | 0% | -$7,358 | |||||
2025-08-26 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | CEO | S - Sale | $1.80 | -10,494 | 121,506 | -8% | -$18,900 | ||||||
| D | 2025-08-26 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Patient Officer | S - Sale+OE | $6.12 | -80,000 | 366,322 | -18% | -$489,680 | |||||
2025-08-21 | ARDX | Ardelyx, Inc. | Kelliher Mike | Chief Business Officer | S - Sale | $5.93 | -5,417 | 276,741 | -2% | -$32,132 | ||||||
2025-08-26 | QTTB | Q32 Bio Inc. | Violette Shelia M. | Chief Scientific Officer | S - Sale | $1.80 | -2,990 | 94,661 | -3% | -$5,385 | ||||||
2025-08-26 | QTTB | Q32 Bio Inc. | Kalowski Lee | CFO, Pres | S - Sale | $1.80 | -4,240 | 49,010 | -8% | -$7,636 | ||||||
| DM | 2025-08-26 | SION | Sionna Therapeutics, Inc. | Cloonan Michael | Pres, CEO | S - Sale+OE | $24.97 | -25,000 | 547,343 | -4% | -$624,361 | |||||
| M | 2025-08-26 | SION | Sionna Therapeutics, Inc. | Ridloff Elena | CFO, Head of Corp. Dev. | S - Sale | $25.70 | -23,416 | 48,116 | -33% | -$601,858 | |||||
| D | 2025-08-27 | CPRX | Catalyst Pharmaceuticals, Inc. | Tierney David S | Dir | S - Sale+OE | $20.20 | -26,000 | 379,620 | -6% | -$525,200 | |||||
| D | 2025-08-26 | CPRX | Catalyst Pharmaceuticals, Inc. | Miller Steve | Chief Op., Scientific Officer | S - Sale+OE | $20.28 | -115,000 | 1,059,663 | -10% | -$2,332,200 | |||||
| D | 2025-08-26 | CPRX | Catalyst Pharmaceuticals, Inc. | Daly Richard J | Pres, CEO | S - Sale+OE | $20.62 | -22,970 | 226,794 | -9% | -$473,641 | |||||
| M | 2025-08-26 | RLMD | Relmada Therapeutics, Inc. | Traversa Sergio | CEO | P - Purchase | $0.67 | +265,976 | 1,000,000 | +36% | +$178,095 | |||||
| D | 2025-08-26 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Chief Scientific Officer | S - Sale+OE | $14.60 | -100,000 | 23,400 | -81% | -$1,459,760 | |||||
2025-08-27 | AMRX | Amneal Pharmaceuticals, Inc. | Kiely John | Dir | S - Sale | $9.23 | -32,000 | 225,433 | -12% | -$295,360 | ||||||
2025-08-28 | LLY | Eli Lilly & Co | Zakrowski Donald A | SVP, Finance, CAO | S - Sale | $734.93 | -1,000 | 5,565 | -15% | -$734,930 | ||||||
2025-08-27 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $17.31 | -470 | 92,656 | -1% | -$8,136 | ||||||
2025-08-27 | RCKT | Rocket Pharmaceuticals, Inc. | Bjork Elisabeth | Dir | P - Purchase | $3.41 | +10,000 | 40,000 | +33% | +$34,100 | ||||||
2025-08-25 | OCUL | Ocular Therapeutix, Inc | Kaiser Peter | Chief Development Officer | S - Sale | $12.04 | -3,011 | 204,093 | -1% | -$36,252 | ||||||
2025-08-25 | OCUL | Ocular Therapeutix, Inc | Nayak Sanjay | Chief Strategy Officer | S - Sale | $12.04 | -1,885 | 279,738 | -1% | -$22,695 | ||||||
2025-08-25 | OCUL | Ocular Therapeutix, Inc | Heier Jeffrey S. | Chief Scientific Officer | S - Sale | $12.04 | -3,063 | 259,911 | -1% | -$36,879 | ||||||
2025-08-25 | OCUL | Ocular Therapeutix, Inc | Dugel Pravin | See Remarks | S - Sale | $12.04 | -21,494 | 3,477,605 | -1% | -$258,788 | ||||||
| DM | 2025-08-25 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $6.95 | -47,674 | 0 | -100% | -$331,418 | |||||
2025-08-25 | NAMS | Newamsterdam Pharma Co N.V. | Kooij Louise Frederika | Chief Accounting Officer | S - Sale | $24.86 | -8,269 | 15,000 | -36% | -$205,567 | ||||||
| D | 2025-08-25 | SUPN | Supernus Pharmaceuticals, Inc. | Mottola Frank | SVP, Quality, GMP, Ops, IT | S - Sale+OE | $44.51 | -14,000 | 15,496 | -47% | -$623,140 | |||||
2025-08-25 | SUPN | Supernus Pharmaceuticals, Inc. | Newhall Charles W III | Dir | S - Sale | $45.00 | -1,000 | 133,232 | -1% | -$45,000 | ||||||
| D | 2025-08-25 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $45.00 | -1,000 | 2,077,059 | 0% | -$45,000 | |||||
| D | 2025-08-25 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $74.62 | -4,000 | 48,034 | -8% | -$298,489 | |||||
2025-08-22 | WVE | Wave Life Sciences Ltd. | Verdine Gregory L. | Dir | S - Sale | $10.00 | -10,000 | 285,217 | -3% | -$100,000 | ||||||
2025-08-22 | WVE | Wave Life Sciences Ltd. | Bolno Paul | Pres, CEO | S - Sale | $10.10 | -217,351 | 121,000 | -64% | -$2,194,810 | ||||||
| D | 2025-08-25 | KALV | Kalvista Pharmaceuticals, Inc. | Sweeny Nicole | Chief Commercial Officer | S - Sale+OE | $13.42 | -1,480 | 32,291 | -4% | -$19,862 | |||||
| D | 2025-08-25 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | Chief Development Officer | S - Sale+OE | $13.42 | -1,954 | 132,052 | -1% | -$26,223 | |||||
| D | 2025-08-25 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $13.42 | -2,336 | 122,505 | -2% | -$31,349 | |||||
| M | 2025-08-22 | AXSM | Axsome Therapeutics, Inc. | Jeffs Roger | Dir | S - Sale | $120.05 | -36,694 | 130,974 | -22% | -$4,405,216 | |||||
| D | 2025-08-22 | CORT | Corcept Therapeutics Inc | Robb Gary Charles | Chief Business Officer | S - Sale+OE | $71.27 | -2,326 | 36,506 | -6% | -$165,774 | |||||
2025-08-22 | EOLS | Evolus, Inc. | Yamagishi-Dressler Tomoko | CMO | S - Sale | $7.51 | -5,722 | 89,949 | -6% | -$42,972 | ||||||
2025-08-25 | ANIP | Ani Pharmaceuticals Inc | Leonard Matthew J | Dir | S - Sale | $90.62 | -2,528 | 6,864 | -27% | -$229,087 | ||||||
2025-08-22 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $61.03 | -2,287 | 1,062,170 | 0% | -$139,576 | ||||||
2025-08-22 | IONS | Ionis Pharmaceuticals Inc | Diaz Allene M. | Dir | S - Sale | $42.53 | -1,427 | 18,368 | -7% | -$60,687 | ||||||
| D | 2025-08-22 | ELTP | Elite Pharmaceuticals Inc /Nv/ | Elite Pharmaceuticals Inc /Nv/ | EVP Operations | S - Sale+OE | $0.52 | -500,000 | 4,300,000 | -10% | -$262,150 | |||||
| D | 2025-08-22 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Chief Med, Dev Officer | S - Sale+OE | $30.43 | -30,000 | 66,270 | -31% | -$912,900 | |||||
2025-08-22 | SUPN | Supernus Pharmaceuticals, Inc. | Newhall Charles W III | Dir | S - Sale | $45.00 | -1,412 | 134,232 | -1% | -$63,540 | ||||||
2025-08-22 | SUPN | Supernus Pharmaceuticals, Inc. | Dec Timothy C | Senior Vice-Pres, CFO | S - Sale | $44.49 | -11,780 | 1,246 | -90% | -$524,092 | ||||||
2025-08-22 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures Iv, L.P. | 10% | S - Sale | $7.00 | -302,194 | 15,456,881 | -2% | -$2,115,358 | ||||||
| D | 2025-08-22 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $45.00 | -1,500 | 2,076,448 | 0% | -$67,500 | |||||
2025-08-22 | DRRX | Durect Corp | Asen R Scott | 10% | P - Purchase | $1.92 | +5,917 | 3,642,529 | 0% | +$11,357 | ||||||
| M | 2025-08-22 | RNXT | Renovorx, Inc. | Bagai Shaun | CEO | P - Purchase | $0.93 | +10,000 | 330,040 | +3% | +$9,297 | |||||
| D | 2025-08-22 | KALV | Kalvista Pharmaceuticals, Inc. | Sweeny Nicole | Chief Commercial Officer | S - Sale+OE | $13.22 | -1,864 | 28,771 | -6% | -$24,647 | |||||
2025-08-21 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Patient Officer | S - Sale | $5.93 | -6,261 | 396,322 | -2% | -$37,138 | ||||||
2025-08-21 | ARDX | Ardelyx, Inc. | Renz Justin A | CFO | S - Sale | $5.93 | -7,037 | 409,052 | -2% | -$41,741 | ||||||
2025-08-21 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $5.93 | -45,687 | 1,527,614 | -3% | -$271,002 | ||||||
2025-08-21 | ARDX | Ardelyx, Inc. | Grammer Elizabeth A | See Remarks | S - Sale | $5.93 | -5,841 | 305,890 | -2% | -$34,647 | ||||||
2025-08-21 | ARDX | Ardelyx, Inc. | Foster Eric Duane | Chief Commercial Officer | S - Sale | $5.93 | -15,308 | 301,498 | -5% | -$90,802 | ||||||
| D | 2025-08-21 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $100.07 | -4,188 | 8,509 | -33% | -$419,091 | |||||
| D | 2025-08-22 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | Chief Development Officer | S - Sale+OE | $13.22 | -2,362 | 130,881 | -2% | -$31,232 | |||||
| M | 2025-08-21 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.77 | -5,710 | 4,422,877 | 0% | -$10,120 | |||||
| D | 2025-08-22 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $13.22 | -10,940 | 386,858 | -3% | -$144,657 | |||||
| D | 2025-08-22 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $13.22 | -2,942 | 119,841 | -2% | -$38,901 | |||||
| D | 2025-08-22 | JNJ | Johnson & Johnson | Duato Joaquin | CEO, COB | S - Sale+OE | $179.21 | -125,824 | 407,793 | -24% | -$22,548,655 | |||||
| M | 2025-08-21 | NAMS | Newamsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | S - Sale | $24.72 | -100,000 | 69,302 | -59% | -$2,471,640 | |||||
| M | 2025-08-22 | AMRX | Amneal Pharmaceuticals, Inc. | Shah Nikita | EVP | S - Sale | $9.65 | -120,832 | 146,403 | -45% | -$1,166,223 | |||||
2025-08-22 | ANIP | Ani Pharmaceuticals Inc | Davis Krista | SVP, CHRO | S - Sale | $91.10 | -1,763 | 62,896 | -3% | -$160,609 | ||||||
2025-08-21 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $2.79 | +3,508 | 1,040,494 | 0% | +$9,797 | ||||||
2025-08-22 | DVAX | Dynavax Technologies Corp | Myers Scott Dunseth | Dir | P - Purchase | $10.82 | +3,800 | 35,004 | +12% | +$41,116 | ||||||
| D | 2025-08-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $11.72 | -100,000 | 1,653,585 | -6% | -$1,172,000 | |||||
| M | 2025-08-21 | DVAX | Dynavax Technologies Corp | Deep Track Biotechnology Master Fund, Ltd. | 10% | S - Sale | $10.82 | -2,065,137 | 15,726,349 | -12% | -$22,351,598 | |||||
| M | 2025-08-21 | SKYE | Skye Bioscience, Inc. | Schwab Andrew J. | Dir, 10% | S - Sale | $3.46 | -231,405 | 9,681,763 | -2% | -$800,549 | |||||
| M | 2025-08-21 | SKYE | Skye Bioscience, Inc. | 5Am Partners Vii, LLC | 10% | S - Sale | $3.46 | -231,405 | 9,681,763 | -2% | -$800,549 | |||||
| M | 2025-08-20 | ANIP | Ani Pharmaceuticals Inc | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS | S - Sale | $90.36 | -100,000 | 529,508 | -16% | -$9,036,008 | |||||
| D | 2025-08-22 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale+OE | $46.40 | -2,208 | 38,867 | -5% | -$102,462 | |||||
2025-08-21 | BBIO | Bridgebio Pharma, Inc. | Trimarchi Thomas | Pres, CFO | S - Sale | $49.48 | -42,237 | 421,081 | -9% | -$2,090,081 | ||||||
2025-08-20 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $48.82 | -26,156 | 5,857,223 | 0% | -$1,276,927 | ||||||
| D | 2025-08-20 | AMRX | Amneal Pharmaceuticals, Inc. | Boyer Andrew S | EVP | S - Sale+OE | $9.38 | -279,244 | 152,426 | -65% | -$2,619,309 | |||||
| D | 2025-08-21 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $308.75 | -11,000 | 36,781 | -23% | -$3,396,249 | |||||
2025-08-21 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $14.49 | -50,000 | 11,303,141 | 0% | -$724,345 | ||||||
| D | 2025-08-21 | SPRY | Ars Pharmaceuticals, Inc. | Scott Kathleen D. | CFO | S - Sale+OE | $15.00 | -12,500 | 18,292 | -41% | -$187,500 | |||||
2025-08-21 | BHC | Bausch Health Companies Inc. | Lee Frank D. | Dir | S - Sale | $7.66 | -15,912 | 73,795 | -18% | -$121,886 | ||||||
2025-08-21 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $10.54 | -7,257 | 67,571 | -10% | -$76,518 | ||||||
2025-08-21 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $10.54 | -1,004 | 15,845 | -6% | -$10,586 | ||||||
2025-08-21 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | CFO | S - Sale | $10.54 | -1,453 | 25,306 | -5% | -$15,320 | ||||||
2025-08-21 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $10.54 | -1,453 | 15,504 | -9% | -$15,320 | ||||||
2025-08-22 | PRGO | Perrigo Co Plc | Willis Robert | EVP, CHRO | P - Purchase | $24.10 | +1,488 | 41,939 | +4% | +$35,858 | ||||||
| M | 2025-08-20 | DRRX | Durect Corp | Asen R Scott | 10% | P - Purchase | $1.89 | +204,220 | 3,636,612 | +6% | +$386,666 | |||||
| M | 2025-08-19 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $15.82 | -4,188 | 104,811 | -4% | -$66,250 | |||||
| D | 2025-08-19 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale+OE | $26.59 | -725 | 19,668 | -4% | -$19,278 | |||||
| D | 2025-08-19 | NKTR | Nektar Therapeutics | Wilson Mark Andrew | GC | S - Sale+OE | $26.59 | -676 | 20,312 | -3% | -$17,975 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |